Case Study 3: Production of key intermediate for HCV (Hepatitis C) drug
Current Production
Highlights:
- Starting material is not readily available
- Reduction process is expensive, dangerous, and extremely low yielding
- Product is highly unstable oil, hard to purify and handle; salt formation requires extra step
Radiant Production
Highlights:
- Inexpensive starting material extending to all halogenated family members
- No dangerous reduction step employed
- Product is highly stable, highly crystalline; no purification is required (direct filtration gives high-purity product)
- Process scalable for MT production